This site is intended for healthcare professionals

European Commission approves Skyrizi to treat psoriatic arthritis.-AbbVie

Read time: 1 mins
Last updated:20th Dec 2021
Published:18th Nov 2021
AbbVie has announced that the European Union's European Commission has approved Skyrizi (risankizumab) for the treatment of adults with active psoriatic arthritis. Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with psoriasis.

The EC approval was based on data from two Phase III studies evaluating Skyrizi in psoriatic arthritis patients, KEEPsAKE-1 and KEEPsAKE-2. In these studies, SKYRIZI met the primary endpoint of ACR20 response at week 24 versus placebo. The approval is for Skyrizi (risankizumab, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate or MTX, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying anti-rheumatic drugs or DMARDs.

Condition: Psoriatic Arthritis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.